Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Yusuke Okuma

ResearcherPublications, citations & collaboration network

Yusuke Okuma is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 389 works, 4,316 citations, an h-index of 31 and an i10-index of 107.

389
Works
4,316
Citations
31
h-index
107
i10-index

How has Yusuke Okuma's publication output changed over time?

ScholarIQpublication output · 2014–2024

Output grew0% over the shown period — from 1 works in 2014 to 1 in 2024.

1
1
1
2
3
1
1
1
20142016201820192020202220232024

What are the most-cited papers on Yusuke Okuma?

ScholarIQmost cited works
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
Taiki Hakozaki, Corentin Richard, Arielle Elkrief, Yukio Hosomi, Myriam Benlaïfaoui, Iris Mimpen, Safae Terrisse, Lisa Derosa, Laurence Zitvogel, Bertrand Routy, Yusuke Okuma
S2765010658. 2020308 Citations
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto
The Lancet Oncology. 2020214 Citations
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
Takashi Kohno, Mamoru Kato, Shinji Kohsaka, Tomohisa Sudo, Ikuo Tamai, Yuichi Shiraishi, Yusuke Okuma, Daisuke Ogasawara, Tatsuya Suzuki, Teruhiko Yoshida, Hiroyuki Mano
Cancer Discovery. 2022208 CitationsOPEN ACCESS
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, Kageaki Watanabe, Yukiko Sagawa, Sadamu Homma
Lung Cancer. 2016179 Citations
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya, Shunsuke Teraoka, Yukari Tsubata, Hiroshige Yoshioka, Yoshihiro Hattori, Chiyo K. Imamura, Yuki Katsuya, Reiko Matsui, Yuji Minegishi, Hidenori Mizugaki, Kaname Nosaki, Yusuke Okuma, Setsuko Sakamoto, Takashi Sone, Kentaro Tanaka, Shigeki Umemura, Takeharu Yamanaka, Shinsuke Amano, Kazuo Hasegawa, Satoshi Morita, Kazuko Nakajima, Makoto Maemondo, Takashi Seto, Nobuyuki Yamamoto
International Journal of Clinical Oncology. 2019154 CitationsOPEN ACCESS

Related on ScholarIQ

National Cancer Center Hospital East
Institution
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
Paper
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Paper
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
Paper
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Paper
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Paper
470M+ articles · free account